# Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

> **NCT03745274** · PHASE1 · COMPLETED · sponsor: **AVIR Green Hills Biotechnology AG** · enrollment: 36 (actual)

## Conditions studied

- Influenza, Avian

## Interventions

- **BIOLOGICAL:** GHB04L1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03745274
- **Lead sponsor:** AVIR Green Hills Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-19
- **Primary completion:** 2009-05-27
- **Final completion:** 2009-05-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745274, "Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03745274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*